Rafael Pharmaceuticals’ Devimistat (CPI-613) Receives EMA’s ODD for R/R Acute Myeloid Leukemia (AML) and Metastatic Pancreatic Cancer (mPC)

 Rafael Pharmaceuticals’ Devimistat (CPI-613) Receives EMA’s ODD for R/R Acute Myeloid Leukemia (AML) and Metastatic Pancreatic Cancer (mPC)

Rafael Pharmaceuticals’ Devimistat (CPI-613) Receives EMA’s ODD for R/R Acute Myeloid Leukemia (AML) and Metastatic Pancreatic Cancer (mPC)

Shots:
  •   The ODD designation is based on the study results assessing devimistat + high dose cytarabine & mitoxantrone and devimistat + folfirinox in patients with r/r AML and mPC respectively
  •  R/R AML study results: CR + Cri (52%); mOS (12.4 mos.), mPC study results: ORR (61%); mOS (19.9
    mos.); mPFS (9.9 mos.), with safe results as monothx and in combination+ SoC drugs respectively
  •  Devimistat (CPI-613) is a novel AMD (altered Metabolism Directed) based drug targeting cancer cells
    and has received ODD from the US FDA for pancreatic cancer, AML, MDS, peripheral T-cell lymphoma and Burkitt lymphoma. Devimistat is being evaluated in seven trials for hematological malignancies and solid tumors
Click here to read full press release/ article | Ref: Globenewswire | Image: Linkedin

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post